Acta cardiologica · 2026
Presence of anti-cardiac troponin I antibodies (cTnIAb) and their role in the left ventricular remodelling, in patients with acute myocardial infarction.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
González-Rojas Andrea Del V, González Maite, Donis José, Peterson Darrell L, Salmen Siham
Аннотация
BACKGROUND: Anti-cardiac troponin I antibodies (cTnIAb) have been demonstrated in patients with acute coronary syndrome (ACS); however, their clinical relevance and impact on patient outcomes remain to be elucidated.
METHODS: An enzyme-linked immunosorbent assay was developed to detect cTnIAb in the serum of patients diagnosed with acute myocardial infarction (AMI). Twenty-three patients with AMI were recruited, and autoantibody levels, clinical, paraclinical, and echocardiographic findings were analysed upon hospital admission and after a six-month follow-up period.
RESULTS: The mean age of the patients was 62.43 ± 13.7 years; on admission, 17 (73.9%) had positive cTnIAb, and 6 (26.1%) had no detectable cTnIAb. At 6 months, 5 (83.3%) of the initially negative patients became cTnIAb positive, while 1 (16.7%) remained negative. Proportions of ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) were 18 (78.2%) and 5 (21.7%), respectively. Positive cTnIAb at admission was associated with greater left ventricular end-diastolic volume (LVEDV) (r = 0.788, p = 0.0023) and left ventricular end-systolic volume (LVESV) (r = 0.696, p = 0.0011) after six months.
CONCLUSIONS: Patients with AMI and pre-existing anti-cTnI antibodies show a positive correlation between cTnIAb titres and LVEDV and LVESV, suggesting potential predictive value for cardiac remodelling following the acute event. Further studies are needed to clarify the clinical significance of these autoantibodies.
METHODS: An enzyme-linked immunosorbent assay was developed to detect cTnIAb in the serum of patients diagnosed with acute myocardial infarction (AMI). Twenty-three patients with AMI were recruited, and autoantibody levels, clinical, paraclinical, and echocardiographic findings were analysed upon hospital admission and after a six-month follow-up period.
RESULTS: The mean age of the patients was 62.43 ± 13.7 years; on admission, 17 (73.9%) had positive cTnIAb, and 6 (26.1%) had no detectable cTnIAb. At 6 months, 5 (83.3%) of the initially negative patients became cTnIAb positive, while 1 (16.7%) remained negative. Proportions of ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) were 18 (78.2%) and 5 (21.7%), respectively. Positive cTnIAb at admission was associated with greater left ventricular end-diastolic volume (LVEDV) (r = 0.788, p = 0.0023) and left ventricular end-systolic volume (LVESV) (r = 0.696, p = 0.0011) after six months.
CONCLUSIONS: Patients with AMI and pre-existing anti-cTnI antibodies show a positive correlation between cTnIAb titres and LVEDV and LVESV, suggesting potential predictive value for cardiac remodelling following the acute event. Further studies are needed to clarify the clinical significance of these autoantibodies.